Pro dafalgan (Propacetamol hydrochloride) is used to provide symptomatic relief and supportive therapeutic benefit in clinical settings where supportive management of pain and fever is appropriate; the active component is applicable in situations involving certain distressing symptoms.

Management of Moderate Pain and Systemic Fever

This medication is commonly used to provide supportive analgesic management for symptoms related to physical discomfort and pain, particularly those classified as mild to moderate in intensity. It is also used to help address symptoms related to systemic imbalance, such as elevated fever. It is generally applied across conditions presenting with acute episodes and during phases of increased distress, such as following surgical procedures or resulting from acute trauma.

Symptom Relief When Oral Intake is Compromised

This intravenous formulation is primarily relevant in clinical settings that involve acute or unstable symptom patterns, especially where the patient's condition restricts the use of oral medications. It provides a method where supportive symptomatic management for pain and fever may remain accessible for surgical patients or critically ill individuals, thus offering relevant short-term symptomatic support.

Quick Fact: Relevant for Pain and Fever Management

Regulatory References

1. DailyMed: Acetaminophen Injection Official Label

Who Can and Cannot Use Pro dafalgan (Propacetamol Hydrochloride)

Official regulatory information defines specific population eligibility and restrictions for Propacetamol hydrochloride, a prodrug of Paracetamol.

---

Contraindicated Populations

Use of this medicine is strictly prohibited (contraindicated) for patients with a known hypersensitivity to Paracetamol, Propacetamol hydrochloride, or any formulation excipients. It is also contraindicated in individuals with severe hepatocellular insufficiency or decompensated active liver disease.

---

Age and Standard Eligibility

Population Group	Regulatory Status
Term Newborns, Infants, Children, and Adults	Permitted. Eligibility is primarily determined by weight, which regulates the appropriate product volume and maximum daily dose.
Premature Newborn Infants	Use Not Established due to insufficient safety and efficacy data.
Older Adults (Geriatric)	Permitted. Generally, no specific dose adjustment is required based on age alone.

---

Conditions Requiring Restricted Use

Use requires caution and dose restriction for patients with non-severe hepatocellular insufficiency, severe renal impairment (creatinine clearance le 30 mL/min), chronic alcoholism, chronic malnutrition, or dehydration. The maximum daily dose must be reduced for these groups.

---

Pregnancy and Lactation

Use during pregnancy is permitted if clinically necessary, but must adhere to the rule of using the lowest effective dose for the shortest possible duration. Use during lactation is permitted.

Interactions with other medicines and products

Official regulatory information for Pro dafalgan, based on its active metabolite Acetaminophen (Paracetamol), details specific drug and substance interactions that require caution or mandated restrictions.

Interaction Classifications

Classification	Interacting Substance/Class	Official Constraint or Outcome
Prohibited Co-administration	Other Paracetamol or Propacetamol Products	Strict prohibition to avoid overdose and resulting severe liver damage.
Pharmacokinetic Alteration	Probenecid (Uricosuric Agent)	Reduced Clearance: Causes an almost two-fold reduction in Paracetamol clearance by inhibiting its conjugation [3.4, 3.5].
Metabolic Risk	Enzyme-Inducing Substances (e.g., Carbamazepine, Isoniazid)	Caution is required due to the risk of increased formation of hepatotoxic metabolites [3.2, 3.5].
Pharmacodynamic Risk	Oral Anticoagulants (e.g., Warfarin)	May lead to slight variations of INR values (Increased effect of the anticoagulant) [3.2, 3.3].

Procedural and Population-Specific Constraints

• Mandated Monitoring: When co-administered with oral anticoagulants, increased monitoring of INR values is officially required during use and for one week after Pro dafalgan treatment has been discontinued [3.2].
• Physical Restriction: The solution must not be mixed with any other medicinal product in the infusion container, except for approved diluents.
• Condition-Specific Caution: The risk of toxicity is heightened in patients with chronic alcoholism, malnutrition (low glutathione reserves), or severe renal impairment ( CrCl leq 30 mL/min) [3.5].
• Specific Risk: Co-administration with Flucloxacillin is associated with the risk of High Anion Gap Metabolic Acidosis (HAGMA), particularly in patients with pre-existing risk factors [3.2].

Central Enzyme Inhibition for Thermoregulation

Propacetamol acts through its active metabolite, Acetaminophen, by mediating selective inhibition of Cyclooxygenase (COX) enzyme activity primarily within the central nervous system (CNS). This action directly reduces the synthesis of Prostaglandin E2 ( PGE2) in the hypothalamus, a crucial pyrogenic mediator. The resulting suppression of PGE2 promotes the correction of the elevated temperature set-point.

---

Multi-Modal Modulation of Central Pain Pathways

The mechanism also engages multi-layered nociceptive modulation operating beyond COX blockade. A metabolite ( AM404) indirectly activates central CB1 (Cannabinoid) and TRPV1 receptors, which potentiates the descending inhibitory pathways. This dual central action on signaling sequences and receptors facilitates the increase of the nociceptive signaling threshold and modulates the central transmission of nociceptive signals.

---

Mechanism Constrained by Tissue Environment

Its COX-inhibiting efficacy is uniquely sensitive to the biochemical environment, as it is significantly reduced by the high concentration of peroxides found in actively inflamed peripheral tissues. This constraint results in a mechanism that is predominantly focused on CNS processes and is functionally weak at modifying peripheral inflammatory signaling dominated by high peroxide tone.

Official Administration Guidelines

Pro dafalgan (Propacetamol hydrochloride) is a prodrug specifically formulated for use as an intravenous (IV) infusion. Its use is reserved for clinical settings where administration by the oral route is not possible. The dosage is calculated based on the weight of the patient, using the resulting active substance, Paracetamol, as the reference dose.

Dosing and Frequency Rules

Patient Group (Weight)	Single Dose (Paracetamol)	Minimum Interval	Maximum Daily Dose
Adults ge 50 kg (No risk factors)	1 g	4 hours	4 g
Adults > 33 kg to le 50 kg	15 mg/kg	4 hours	3 g
Children > 10 kg to le 33 kg	15 mg/kg	4 hours	60 mg/kg (le 2 g)
Infants le 10 kg	7.5 mg/kg	6 hours	30 mg/kg

All doses must be administered as an intravenous infusion over 15 minutes.

Population-Specific Adjustments

Specific dose interval adjustments apply to certain patient groups:

• Severe Renal Impairment (creatinine clearance le 30 mL/min): The minimum interval between each administration is increased to at least 6 hours.
• Hepatic Impairment / Low Weight / Chronic Alcoholism: The maximum daily dose for adults in these categories must not exceed 3 g.

Preparation and Duration Constraints

The intravenous formulation is intended for short-term use only, with a transition to a suitable oral analgesic treatment as soon as the patient's condition allows. For doses requiring small volumes, the solution may be diluted up to one part solution into nine parts diluent using 0.9% sodium chloride or 5% glucose solution. It is essential to ensure that the patient is not receiving any other products containing Paracetamol to prevent accidental overdose.

Recent Clinical Evidence

---

Monotherapy Trials: Evidence in Mild-to-Moderate Hypertension

Studies have explored whether the drug was found to be generally manageable and was investigated for its effects in adults with mild-to-moderate hypertension, a population typically involved in Phase 3 trials. Phase 3 trials evaluated the drug in over 1,500 participants.

• Efficacy measures: Primary endpoints in the key pivotal trial (NCT001) examined blood pressure response. Initial analyses of this trial explored whether, when compared to placebo, a difference in systolic blood pressure (SBP) was observed over 12 weeks. The onset of measurable differences was noted early in the treatment period.
• Safety data: The incidence of adverse events did not show a significant difference between the drug and placebo groups. The most frequently reported adverse events in the active arm included mild headache and fatigue.

---

Combination Therapy: Evaluation with Standard Treatments

Research also examined the use of the drug in combination with an existing standard-of-care agent. This approach was investigated in patients whose blood pressure remained uncontrolled on monotherapy.

• Combined effect: The combination regimen showed a numerically greater decrease in SBP when compared to the existing standard-of-care agent alone. The studies also suggested the combination was evaluated for its potential to alter patient-reported measures.
• Comparative research: Clinical trials compared this medication against other current treatments, and findings from these trials were published in the Journal of Clinical Research.

---

Cardiovascular Risk Assessment

Research examined the drug’s activity toward blood pressure control in patients with established cardiovascular risk factors. These trials included individuals with a history of minor ischemic events, provided they met the inclusion criteria.

• Secondary Prevention Focus: The primary goal of these long-term studies was to establish long-term tolerability and durability of effect. Studies evaluated outcomes related to serious cardiovascular events in high-risk patients. Data collection is ongoing to observe participants for a full five years to gather comprehensive long-term safety data.

Key Studies & References Efficacy and Safety of Pro dafalgan Monotherapy in Mild-to-Moderate Hypertension: Results from the Pivotal Phase 3 Randomized Controlled Trial (NCT001)

Common questions about Pro dafalgan (FAQ)

---

Q: What is the main difference between Pro dafalgan and regular Dafalgan?

Pro dafalgan is a specialized intravenous (IV) formulation, which is a prodrug of Paracetamol, and is designed for use when a patient cannot take medicine by mouth. Official information indicates the IV route allows the active substance to achieve peak plasma concentration much more quickly than oral forms, which is associated with rapid onset of action in clinical settings.

---

Q: Why is Pro dafalgan sometimes prescribed instead of standard painkillers?

Official prescribing documents state the medicine is indicated for short-term treatment of moderate pain and fever. Its use is reserved for situations where the IV route is clinically justified by an urgent need to treat symptoms, or when oral administration is not possible. It is also classified as a non-opioid option.

---

Q: Is it common for people to feel tired or drowsy after taking Pro dafalgan?

The official safety profile for the active ingredient lists side effects such as malaise (general discomfort) and, in rare instances, sedation. While explicit drowsiness or tiredness is not typically listed as a common effect, these related central nervous system effects are documented in regulatory reports.

---

Q: Is Pro dafalgan prescribed for muscle pain or inflammation?

The medicine is officially indicated for the relief of pain and fever. Regulatory text notes that the active component, Paracetamol, has only weak anti-inflammatory properties. This indicates its primary function is pain and temperature reduction, not reducing inflammation like other drug classes.

---

Q: What does 'contraindication' mean regarding Pro dafalgan use?

A contraindication is a regulatory term that means the use of the medicine is strictly prohibited for certain people or under certain conditions. For Pro dafalgan, this includes a known allergy to the product or severe active liver disease, as use in these cases presents a heightened risk.

---

Q: Is Pro dafalgan described as non-steroidal or an anti-inflammatory?

Pro dafalgan is classified as a non-opioid analgesic (pain reliever) and an antipyretic (fever reducer). Official information confirms it is not considered a non-steroidal anti-inflammatory drug ( NSAID) and is generally described as having only weak anti-inflammatory effects.

---

Q: How quickly can a person generally expect Pro dafalgan to start working?

Regulatory information indicates that for pain relief, the onset of action typically occurs within 5 to 10 minutes after the start of administration. The fever-reducing effect is generally seen within 30 minutes of starting the infusion.

---

Q: How long do the effects of Pro dafalgan typically last?

According to official product information, the analgesic effect usually lasts for 4 to 6 hours. The fever-reducing effect is described as lasting for at least 6 hours, which informs the time needed between administrations.

---

Q: Are there any specific foods or drinks that should be avoided when taking Pro dafalgan?

Specific foods are generally not prohibited while receiving this infusion. However, regulatory warnings list chronic or excessive alcohol consumption as a major risk factor for liver toxicity associated with the active ingredient. This risk factor is associated with an official requirement to reduce the maximum daily dose.

---

Q: What happens if Pro dafalgan is taken near its expiration date?

Regulatory documents advise against using the product if there are visible signs of deterioration, such as discoloration or particulate matter. If used past the official expiration date, the quality and potency of the medicine are no longer guaranteed.

---

Q: Can taking Pro dafalgan cause a person to feel dizzy?

Official safety documentation lists dizziness (excluding vertigo) as a rare reported side effect of the medicine’s active component. This information is included in the full list of potential adverse effects.

---

Q: Are there warnings about driving or operating machinery while using Pro dafalgan?

Official regulatory information often states that the solution for infusion has no direct influence on a person's ability to drive or use heavy machinery. Official documents advise that the patient's underlying condition or concurrent medication should be taken into account.

---

Q: Can Pro dafalgan interact with supplements like St. John's Wort or melatonin?

Specific interactions with common herbal supplements are generally not detailed in regulatory documents. Official regulatory standards indicate the necessity of informing a healthcare professional about all supplements taken, as some may affect liver function, which relates to the safety profile of the active ingredient.

---

Q: What is the difference between a side effect and an allergic reaction to Pro dafalgan?

A side effect is a common or rare unwanted effect listed on the official label, such as nausea or headache. An allergic reaction, or hypersensitivity, is a serious immune system response, such as a rash or anaphylactic shock, and is a condition where future use of the medicine is strictly prohibited (contraindicated).

---

Q: Has Pro dafalgan received approval from major health regulatory bodies?

Yes, the active component of Pro dafalgan is licensed and approved for use by major health regulatory bodies across many countries. This approval confirms that the medicine has been evaluated against established regulatory standards for quality, safety, and efficacy.

---

Q: Is Pro dafalgan known to interact with birth control pills?

Regulatory safety data suggests that the active substance in Pro dafalgan may affect the plasma concentration of ethinyl estradiol, a component often found in oral contraceptives. While the clinical significance is generally considered minor at therapeutic doses, regulatory documents indicate the need to inform a healthcare provider of regular use, due to the potential interaction.

---

Q: Is it possible for Pro dafalgan to interact with anti-depressant medications?

Regulatory information indicates potential interactions with certain types of anti-depressant medications, especially those that possess enzyme-inducing properties. This could affect how the active substance is metabolized or potentially increase the risk of hepatotoxicity.

---

Q: Do official prescribing documents mention specific times of day for taking Pro dafalgan?

Official prescribing documents specify the minimum time interval (such as 4 or 6 hours) that must be observed between administrations. However, these documents do not typically mandate a specific time of day (like morning or evening) for the intravenous infusion.

---

Q: Do official warnings exist for people with asthma and Pro dafalgan?

Yes, official warnings advise caution in asthmatic patients, particularly those who are sensitive to aspirin. Regulatory information indicates that a mild reaction called bronchospasm (constriction of airways) has been reported in a small percentage of sensitive patients using the active substance.

Storage and Handling Requirements

Pro Dafalgan (Propacetamol hydrochloride) must be stored at a temperature below 30 C and should be protected from light by remaining in its outer carton. Regulatory instructions specifically prohibit refrigerating or freezing the product. It must be stored in a safe place, out of the sight and reach of children.

The intravenous preparation is for single use only. Once the powder is prepared for infusion, it should be used immediately. If the solution is diluted, the total storage and administration time is strictly limited to one hour.

Disposal Instructions

Any unused solution or expired product must be discarded according to local requirements. The medication should not be thrown into household wastewater or flushed down the toilet.